Advertisement

Colorectal Cancer

Multiple Means to Realize the Benefits of Colorectal Cancer Screening

In an updated recommendation statement, the U.S. Preventive Services Task Force (USPSTF) continues to strongly recommend screening for colorectal cancer for asymptomatic adults...

Breast Cancer

Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab/capecitabine was noninferior...

Global Cancer Care

Making a Difference in the Lives of Others

Quyen D. Chu, MD, MBA, FACS, this year’s recipient of ASCO’s Humanitarian Award, lives by the axiom that “One person can make a positive difference in the lives of others.” ...


Advertisement

More Top Stories

Breast Cancer

Nikhil Wagle, MD, on The Metastatic Breast Cancer Project: Progress Report

Colorectal Cancer

Multiple Strategies for Colorectal Cancer Screening Offer an Opportunity for Shared Decision-Making

Screening for colorectal cancer should start at age 50 and continue until age 75, according to the updated recommendation from the U.S. Preventive Services Task Force (USPSTF).1 “Exactly what screening gets done is something that doctors and patients should decide together,” USPSTF Chair Kirsten...

Advertisement

Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...

Pancreatic Cancer

John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial

Issues in Oncology

Effects of the Global Economic Crisis on Cancer Care

The global economic crisis beginning in 2008 was associated with substantial public health effects, especially with respect to mental health.1–3 Nevertheless, there is also evidence of a paradoxical association between recessions and reduced all-cause mortality, in part because of reductions in...

Issues in Oncology

ASCO and Friends of Cancer Research Launch Initiative to Modernize Eligibility Criteria for Clinical Trials

The dismal accrual rates in cancer clinical trials are well known: Just 3% to 5% of adults with cancer enroll in clinical trials.1 The reasons patients are reluctant to participate in clinical trials are equally well known: fear of reduced quality of life, concern about receiving a placebo, and...

Study Finds Effect of Combined Hormone Replacement Therapy on Breast Cancer Risk Likely to Have Been Underestimated

The effect of combined hormone replacement therapy (HRT) in increasing a woman’s risk of breast cancer is likely to have been underestimated by a number of previous studies, according to a new prospective study published by Jones et al in the British Journal of Cancer.

HRT is used to treat...

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on NSCLC: Results from the SQUIRE Trial (Spanish Language Version)

ASTRO Members Elect Five New Officers to Board of Directors

Members of the American Society for Radiation Oncology ­(ASTRO) have elected five new officers to the Society’s Board of Directors, including President-Elect, Secretary/Treasurer-Elect, and Vice-Chairs of three of ASTRO’s five councils (Clinical Affairs and Quality, Education, and Government...

Advertisement

Increased Uveal Melanoma Risk Linked to Pigmentation Genes That Dictate Eye Color

New research links specific inherited genetic alterations to an increased risk for uveal melanoma, a rare form of melanoma that arises from pigment cells that determine eye color. These findings were published by Ferguson et al in Scientific Reports.

Previous clinical data suggests uveal melanoma...